Programme

Programme

Conference Day 1
Monday, 24 August 2020

Conference Day 2
Tuesay, 25 August 2020

Satellite Meetings
Wednesday, 26 August 2020
(date and location tbc)

Conference Day 1

Location:
Congress Center Basel, Foyer 2nd floor, Messeplatz 21, 4058 Basel, Switzerland

Monday, 24 August 2020

09:00–10:30

Pre-conference Meeting

// for BEAM members only – please register via the registration form //

10:30–11:00

Networking Break

11:00–12:30

Pre-conference workshops

11:00–12:00

// Free of charge. Limited seats. You can register via the online registation form //

A joint workshop of IMI AMR Accelerator and Wellcome Trust.

Tackling drug-resistant infections is a huge challenge. While some action is being taken, we are a long way from breakthrough progress. One way to increase the pace of action is to make sure that advocates are using the best available evidence to communicate effectively. Wellcome conducted a year-long multi-country research project to identify the most effective way to frame drug-resistant infections to increase public comprehension and persuade the public and policy makers of the case for action. In this session, Wellcome will present their findings. This will be followed by further insights from AMR stakeholders on communication challenges and a panel discussion. 

The following speakers & panelists have confirmed:

  • Sandra Wirsching, BIOCOM AG & Communication specialist, IMI AMR Acceralator (Moderator)
  • Jeremy Knox, Policy Officer, Wellcome Trust, UK
  • Kevin Outterson, Executive Director, CARB-X, US
  • Marc Lemonnier, CEO, Antabio, FR
  • Sarah Paulin, Technical Officer of Antimicrobial Resistance (AMR) and Innovation, Access and Use, World Health Organization (WHO)
  • Laura Alonso Irujo, Communication specilist, EU-JAMRAI 
 

11:00–12:30

// FULLY BOOKED: If you would like to be added to the waiting list, please send an email to amr@biocom.de  //

Jointly organised by Novo REPAIR Impact Fund, CARB-X, GARDP and Wellcome Trust
           

Moderation:
Ursula Theuretzbacher, CEFAIA

Speakers:

  • Preclinical models (Peter Warn, SVP, Anti-infective Discovery, Evotec)
  • Toxicology (Richard Knight, Director & Co-founder, ApconiX)
  • Formulation (Aleksandar Danilovski, CSO & Senior Vice President Global R&D and Regulatory Affairs, Xellia)

12:30–21:30

Registration, poster presentations and exhibition open

12:30–13:30

Lunch Reception

The reception will be opened by Ambassador Miriam Shearman, UK Deputy Permanent Representative to the UN in Geneva, and will include a panel discussion and Q&A on the “The Investor Year of Action on AMR” initiative recently launched at the World Economic Forum in Davos. Professor Dame Sally Davies, the UK’s Special Envoy for AMR, has also sent a personalised video message to share more information on high priority AMR issues for 2020 and beyond.

Sponsored by:

 

13:30–14:45

Plenary session

Moderation & Introduction: Marc Gitzinger, CEO, BioVersys AG, CH & Vice-President BEAM Alliance

Speakers & Panelists:

  • Kevin Outterson, Executive Director, CARB-X, US
  • Ken Bradley, Global Head Infectious Disease Discovery, Roche
  • Cherif Bousselham, Head of EMEA, Accelerate Diagnostics 
  • Jean-Pierre Paccaud, Director of Business Development and Corporate Strategy, GARDP
  • Louise Norton-SmithHead of Global Antimicrobial Resistance Strategy & Delivery, Global AMR Innovation Fund, UK

14:45–15:45

Plenary session

Supported by: 

Moderation: Erin Duffy, Chief of Research & Development, CARB-X, US

Speakers:

  • Aleks Engel, Partner Novo Seeds and Director, Novo Holdings, REPAIR Impact Fund, US
  • Felicitas Riedl, Head of Life Science Division, European Investment Bank & Peter Beyer, Senior Advisor Antimicrobial Resistance, World Health Organisation
  • Graham Somers, IMI Portfolio Director, R&D Global Health, GSK, UK
  • Jo Raven, FAIRR Investor Network, UK
 
Followed by a panel debate with all speakers

15:45–16:15

Networking Break

15:45–20:30

1-to-1 Partnering Meetings

16:15–17:15

Parallel Tracks

Moderator & Input Talk: 

Johan Vekemans, Medical Officer, Initiative Vaccine Research, World Health Organisation 

Speakers:

  • Johannes Hübner, Head of Dept. of Pediatric Infectious Diseases, Dr. Haunersches Children’s Hospital, LMU Munich, GER
  • Katrine Thor Andersen, TB strategy team, Bill & Melinda Gates Foundation, US
  • Tom Monroe, CEO, Vaxxilon AG, CH
  • Javad Aman, President and CSO, Intergrated BioTherapeutics Inc, US

Moderator & Input Talk: 

Till Bachmann, Deputy Head of Infection Medicine & Personal Chair of Molecular Diagnostics and Infection, University of Edinburgh

Further Speakers:

  • Francis Moussy, Leader Diagnostics & Focal Point for new diagnostics in AMR, WHO
  • Philippe Cleuziat, Innovation Program Senior Director, bioMérieux & Project Lead, VALUE-Dx, FR
  • Achim Plum, Managing Director, Ares Genetics, AUT
  • Weian Zhao, Associate Professor, University of California, US

Moderator & Input Talk:

Isabelle Bekeredjian-Ding,  Head of Division, Microbiology, Paul-Ehrlich Institut, GER

Speakers:

  • Cesar de la Fuente, Presidential Assistant Professor, University of Pennsylvania, US
  • Stie Kallesøe, CEO, grit42, DK
  • Adrian Wildfire, Scientific Director, SGS Life Sciences, UK
  • Dirk Bumann, Biozentrum, The Center for Molecular Life Sciences, University of Basel, CH

17:15–17:45

Networking Break

17:45–18:45

Parallel Tracks

Moderation: Erin Duffy, Chief of Research & Development, CARB-X, US

 

Speakers:

  • Alexander Belcredi, CEO, Phagomed, AUS
  • Oswald Lockhoff, CEO, Sidanis Pharma, GER
  • Timothy Schulz-Utermoehl, Co-founder, Director, Pedanius Therapeutics, UK
  • Amine Zorgani, Head of R&D Mircobiology, Antimicrobials, Nuritas, FR 

This session is organised in cooperation with Longitude Prize

AMR diagnostic technology as a means to accelerate antibiotic product development as well as clinical diagnosis 

Moderator: Longitude Prize, Daniel Berman, Nesta, UK

Speakers & Panelists:

  • Kwangmin Son, CEO, PHAST Inc., US
  • Michael Lobritz, Translational Project Leader, Roche, CH 
  • Henry Chambers, University of California, US & Principal investigator ARLG, NIH
  • Cassandra Kelly-Cirino, Director of Emerging Threats, FINDDx
  • Laurenz Kellenberger, CSO, Basilea, CH

Speakers:

  • Samareh Azeredo da Silveira Lajaunias, Managing Director, Combioxin SA, CH
  • Stefan Hagel, Principal Investigator, Center for Infectious Diseases and Infection Control, Jena University Hospital, GER
  • Shampa Das, Liverpool School of Tropical Medicine and University of Liverpool & Centre of Excellence in Infectious Diseases Research (CEIDR), UK
  • Till Schäberle, Professor, Department of Insect Biotechnology at University of Gießen & Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), GER

18:45–19:00

Networking Break

19:00–19:30

Plenary Session

Supported by:

Pitches:

  • Irene Wütherich, Pioneer Fellow at ETH Zürich & Co-founder, SpheroBiotics, CH
  • Thomas Hesterkamp, Myxobiotics, GER
  • Neciah Dorh, FluoretIQ, UK
  • Miron Tokarski, CEO, Genomtec, PL
  • Patrick Großmann, Co-Founder & Business Lead, Invitris, GER
Start-up pitch jury:
  • Peter Jackson, Executive Director, AMR Centre Ltd, UK (Moderator) 
  • Karen Gallant, Global R&D Director, CARB-X, US
  • Fiona Marston, Director, Centre of Excellence in Infectious Diseases Research (CEIDR), UK
  • João Ribas, Novo Repair Impact Fund, DK

19:30–21:30

Evening Reception in the Exhibition

Sponsored by: 

19:45–20:05 3-minute pitches in the Swiss Area (pitches tba)

20:10–20:30 3-minute pitches by ENABLE supported companies (Juvabis, Oxford, Mutabilis, ABAC)

Conference Day 2

Location:
Congress Center Basel, Foyer 2nd floor, Messeplatz 21, 4058 Basel, Switzerland

Tuesday, 25 August 2020

08:00–18:30

Registration, poster presentations and exhibition open

08:45–10:15

Plenary session

Moderation & Input:  Marc Lemonnier, CEO, Antabio, FR 

Speaker:

  • Sarah Paulin, Technical Officer of Antimicrobial Resistance (AMR) and Innovation, Access and Use, World Health Organization (WHO)
  • Katerina Galluzzo, Technical Manager, Strategy Team, UNITAID 

Followed by a panel debate with the following experts

  • Seamus O’Brien, R&D Director, GARDP
  • Gökhan Batur, CEO, Polyphor, CH
  • Anand Anandkumar, CEO Bugworks, India

10:15–10:45

Networking Break

10:00–16:30

1-to-1 Partnering Meetings

10:45–12:00

Parallel Tracks

This session will be organised in cooperation with GARDP and the support of the Global AMR R&D Hub. 

 


Moderator:
Seamus O’ Brien, Head of R&D, GARDP

Speakers:

  • Julia Bielicki, Attending Physician Pediatric & Pediatric Infectious Diseases, Medical Coordinator ASC, University Hospital Basel, St Georges Hospital, London
  • Sushma Nangia, DM (Neonatology – AIIMS), Director Professor & Head, Department of Neonatology, Lady Hardinge Medical College &, Kalawati Saran, Children’s Hospital, New Delhi, India
  • Jolly Nakunda, Neonatologist, Clinical trials in Uganda 
  • Asian Clinical trial network, Tim Jinks, Head of Infectious Disease Program,  Wellcome Trust, UK
 
Panelists in the round table discussion: 
  • Sumathi Nambiar, Director Division Anti-Infective, Office of Infectious Diseases, CDER, FDA, US 
  • Radu Botgros, Scientific Officer, Anti-infectives and Vaccines, Scientific and Regulatory Management Department, EMA 

  

Moderator & Input Talk:
Robert Skov, Scientific Director, ICARS, DK

Speakers:

  • Peer Davies, Senior Lecturer in Livestock Health and Welfare, Epidemiology and Population Health, University of Liverpool, CEIDR, UK
  • Timo Minssen, Founder and Managing Director, Center for Advanced Studies in Biomedical Innovation Law (CeBIL), DK
  • Ghada Zoubiane, ICARS
  • Viviana Munoz Tellez, Programme Coordinator, Health, IP and Biodiversity (HIPB), South Centre, CH

Supported by:

Moderator & Input Talk:
Elmar Nimmesgern, Secretariat Lead, Global AMR R&D Hub

Speakers & Panelists:

  • Colm Leonhard, Clinical Adviser/Consultant, NICE, UK
  • Jeremy Knox, Policy and Advocy Lead, Wellcome Trust, UK
  • Marcus Guardian, CEO, EUnetHTA Secretariat, NL (tbc)
  • Philippe Cleuziat, Innovation Program Senior Director, bioMérieux & Project Lead VALUE-Dx, FR
  • Daniel Berman, Longitude Prize, Nesta, UK
  • Christoph Spennemann, Legal officer, UNCTAD

12:00–13:30

Lunch

12:45–13:15

Lunch Session 

In this Lunch Session the new Swiss antibiotics R&D network NCCR AntiResist presents its work.

12:45–12:55
Presentation by Prof. Christoph Dehio: «NCCR AntiResist: A new Swiss research program to combat antibiotic resistant bacteria»

12:55–13:10
Presentation by Prof. Dirk Bumann: «Analyzing pathogen physiology in human patients»

13:30–14:30

Parallel Tracks

Moderator & Input Talk:
William Hope
, Professor, University of Liverpool and Head of Centre of Excellence in Infectious Diseases Research (CEIDR), UK

Further speakers:

  • Gisbert Schneider, Professor for Computer-assisted drug-design, Department of Chemistry and Applied Biosciences, ETH Zürich 
  • Glenn Dale, Chief Development Officer, BioVersys, CH
  • Nadine Taudte, Periotrap, GER
  • Andreas Bastian, CEO, AGiLebiotics
  • Paul Finn, CEO, Oxford Drug Discovery, UK

Supported by:

Session Chair & Input Talk: Juan José Vaquero, Professor, Dept. of Bioengineering, Vice-President for Scientific Policy, Universidad Carlos III de Madrid, ESP 

Speakers:

  • Joel LeLievre, Head of External Collaborations for the TB research Unit, GlaxoSmithKline, ESP
  • Florian von Groote-Bidlingmaier, Global Head Executive Vice President – Head of Global Health and Clinical Development Infectious Diseases, Evotec, FR 
  • Michel Pieren, Project Manager, BioVersys AG, CH
  • Florian Kloss, Head, Hans Knöll Institute (HKI), GER & Michael Hoelscher, Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER

Supported by:

Moderator & Input Talk:
Gökhan Batur, CEO, Polyphor, CH

Further speakers:

  • Peter Beyer, Senior Advisor Department of Essential Medicines & Health Products, WHO
  • Clive Mason, Summit Therapeutics plc, UK
  • Colin Denver, CEO, SpeeDX, AUS 
  • Francis Moussy, Leader Diagnostics & Focal Point for new diagnostics in AMR, WHO
  • Erin Duffy, Chief of Research & Development, CARB-X, US

14:30–15:00

Networking Break

15:00–16:00

Parallel Tracks

Session Chair & Input talk: Henry Chambers, University of California, US & Principal investigator ARLG, NIH

Speakers & panelists: 

  • Laurenz Kellenberger, CSO, Basilea Pharmaceutica, CH
  • Philipp Knechtle, Director Microbiology, Allecra, FR
  • Neil Clark, CEO, Destiny Pharma
  • Radu Botgros, Scientific Officer, Anti-infectives and Vaccines, Scientific and Regulatory Management Department, EMA 
  • Sumathi Nambiar, Director Division Anti-Invective, Office of Infectious Diseases, FDA
 

This session is organised together with FINDDx.

Session Chair & Input talk: Anita Suresh, FINDDx

Speakers & panelists:

  • Luis Ceuvas, Chair in International Public Health and Epidemiology, Liverpool School of Tropical Medicine, UK
  • Draurio Barreira, TB Manager, UNITAID
More speakers will be announced soon. 

 

  

  • Fiona Tomley, One Health Poultry Hub, Royal Veterinary College,  UK (requested) 
  • Klaus Hellmann, Klifovet AG, GER
  • N.N., Vetophage (tbc)
  • Joe Fitchett, Medical Director, Mologic, UK (tbc)
  • Peter Harald, Head of IvD-Platform / Point-of-Care Technologies, Fraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses (Fraunhofer IZI-BB), GER

16:00–16:30

Networking Break

16:30–17:00

Plenary session

Supported by:

Panelists:

  • Peter Jackson, Executive Director, AMR Centre Ltd, UK (Moderator) 
  • Karen Gallant, Global R&D Director, CARB-X, US
  • Fiona Marston, Director, Centre of Excellence in Infectious Diseases Research (CEIDR), UK
  • João Ribas, Novo Repair Impact Fund, DK

17:00–19:00

Closing plenary session

// Free of charge. Seats are limited. //

Organised by Swiss National Research Programme “Antimicrobial Resistance” (NRP 72) – Learn more at www.nrp72.ch

Agenda:
Part 1: Connecting politics, industry and academia in Switzerland

10-minute input talks by:

  • Bea Heim, Member of the Swiss National Council 2003–2019, Steering Committee «Round Table Antibiotika»
  • Markus Seeger, SNF Professor and Leader of the Antibiotics Platform, biotechnet / Swiss Biotech Association
  • Marc Gitzinger, CEO BioVersys, Vice-President of the Beam Alliance
  • Daniel Obrecht, CSO, Polyphor
  • Laurenz Kellenberger, CSO, Basilea Pharmaceutica


Discussion with speakers and guests:

  • Stéphanie Lecaudé, Scientific Officer Life Sciences, Project and Programme Funding, Innosuisse
  • Christof Klöpper, CEO, BaselArea.swiss


Part 2: Linking Swiss R&D to international networks

10-minute input talks by:

  • Alexandre von Kessel, International Programme Officer, Global AMR R&D Hub (seconded from the Swiss Federal Office of Public Health)
  • Ken Bradley, Global Head of Infectious Disease Discovery, Roche
  • Seamus O’Brien, R&D Director, Global Antibiotic Research and Development Partnership (GARDP)
  • Kevin Outterson, Professor of Law and Executive Director of CARB-X Global Partnership
  • Anders Karlén, Uppsala University, Project coordinator COMBINE (part of the IMI AMR Accelerator) Discussion with speakers and guests


Malcolm Page
member of the Steering Committee of the Swiss National Research Programme «Antimicrobial Resistance» (NRP 72), the Scientific Advisory Committee of GARDP and the Portfolio Management Committee of the IMI project ENABLE, will chair the workshop and moderate the discussion.

19:00–20:00

Closing reception

Satellite Meeting

Location tbc

Wednesday, 26 August 2020

10:00–22:00

Details on the new time and location will be communicated asap.

Hosted by the IMI AMR Accelerator programme COMBINE WP3 and WP1

// Registration: By invitation only //

Agenda:

10:00–10:45 Registration and Coffee Break
10:45–12:00 Welcome and Introduction: Short pitches by all projects | Overview of afternoon workshops
12:00–13:15 Lunch break

Overview of afternoon workshops:
13:15–14:15 Management and communication
14:15–15:30 Data management
15:30–18:00 Clinical trials and animal models

19:00–22:00 Cross-Pillar Dinner (location tba)

See more event details here

BEAM Alliance programme committee

Marc Lemonnier

CEO, Antabio SAS

Marc Gitzinger

CEO, BioVersys AG, CH & Vice President Board, BEAM Alliance

Marie Petit

Coordinator, BEAM Alliance & Principal, Villiger Valuation